2.10. Analysis.

Comparison 2 RISPERIDONE + CLOZAPINE vs PLACEBO + CLOZAPINE, Outcome 10 Adverse effects: 1b. extrapyramidal ‐ skewed data (various scales) ‐ short term (up to 12 weeks).

Adverse effects: 1b. extrapyramidal ‐ skewed data (various scales) ‐ short term (up to 12 weeks)
Study	Intervention	Mean	SD	N
average endpoint score of AIMS
Yagcioglu 2005	Risperidone	1.3	0.88	16
Yagcioglu 2005	Placebo	1.0	0.86	14
average change score of Barnes akathisia rating scale
Honer 2006	Risperidone	0.5	0.7	32
Honer 2006	Placebo	0.4	0.8	33
Yagcioglu 2005	Risperidone	0.18	0.6	16
Yagcioglu 2005	Placebo	0.72	0.6	14
average change score of ESRS
Honer 2006	Risperidone	9.3	6.9	32
Honer 2006	Placebo	7.8	7.0	32
average change score of ESRS ‐ dystonia
Honer 2006	Risperidone	0.2	0.7	32
Honer 2006	Placebo	0.1	0.5	33
average change score of ESRS ‐ dyskinesia
Honer 2006	Risperidone	2.4	4.1	32
Honer 2006	Placebo	2.1	4.2	33
average change score of ESRS ‐ parkinsonism
Honer 2006	Risperidone	6.7	4.3	32
Honer 2006	Placebo	5.5	4	32